SCHEMBL957142

SCHEMBL957142

CS(=O)(=O)NCc1ccc(B(O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.59
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50
RECQL P46063 1/20 0.50
ENPP2 Q13822 1/20 0.50
LPL P06858 3/20 0.48
LIPG Q9Y5X9 3/20 0.48
TRPV1 Q8NER1 4/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
NAMPT P43490 1/20 0.43
F11 P03951 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5660298 0.84 LPL (0.52) KMT2AKDM4EENPP2LPLLIPG
SCHEMBL5640391 0.82 LPL (0.52) KMT2APOLBRECQLENPP2LPL
SCHEMBL14830139 0.80 MGLL (0.50) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL532278 0.80 ENPP2 (0.51) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL3605085 0.79 KMT2A (0.65) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL7230378 0.79 KMT2A (0.65) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL28159844 0.77 KMT2A (0.54) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL17101792 0.77 CA12 (0.65) KMT2AKDM4ENAMPTSMN1; SMN2CNR2
SCHEMBL3605081 0.76 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL4491485 0.76 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US claimed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP claimed
EP-3344232-B1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY UNIV MCMASTER (CA) 2022-01-26 EP claimed
US-10611908-B2 Micelles for mucoadhesive drug delivery MCMASTER UNIVERSITY (CA) 2020-04-07 US claimed
US-20180265694-A1 Micelles for Mucoadhesive Drug Delivery MCMASTER UNIVERSITY (CA) 2018-09-20 US claimed
EP-3344232-A1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY Mcmaster University (CA) 2018-07-11 EP claimed
WO-2017035656-A1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY MCMASTER UNIVERSITY (CA) 2017-03-09 WO claimed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 EP disclosed
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US disclosed
US-20230139250-A1 FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF EYEPOINT PHARMACEUTICALS INC (US) 2023-05-04 US disclosed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022212194-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2022-10-06 WO disclosed
EP-1896014-A2 CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-03-12 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed
US-20070270415-A1 Benzothiadiazine compounds LESLABORATOIRES SERVIER (FR) 2007-11-22 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed
US-7268130-B2 Benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2007-09-11 US disclosed
WO-2007005534-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-01-11 WO disclosed
US-20060094712-A1 New benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270415-A1 Benzothiadiazine compounds SLC1A1, SLC1A2, SULT2A1 KMT2A 1075/4885KDM4E 3825/4885POLB 1047/4885
US-20060094712-A1 New benzothiadiazine compounds SLC1A1, SLC1A2, GABRA5 KMT2A 1257/4885KDM4E 3767/4885POLB 1407/4885
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 KMT2A 3772/4885KDM4E 3178/4885POLB 3024/4885
US-20230139250-A1 FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF TIE1, TEK, KDR KMT2A 852/4885KDM4E 1190/4885POLB 3471/4885
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES EPX, EPCAM, ELANE KMT2A 3849/4885KDM4E 3727/4885POLB 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.